The FAP Gene Support Group

(Familial Adenomatous Polyposis)

Facebook Icon
Homepage About us Cognitune More studies on Curcumin Comparison of Trials Worldwide Trial  
Curcumin Trials Menu Curcumin Research Curcumin Suppliers Curcumin Personal Trial Desmoid Trial Disclaimer

The FAP Gene Support Group

Was pleased to promote the following trial now closed

Seeking FAP Patients for Phase III Clinical Trial


The trial is being sponsored by Cancer Prevention Pharmaceuticals, Inc

Cancer Prevention Pharmaceuticals, Inc. is developing novel therapeutic agents, diagnostics, and lifestyle recommendations that make possible the treatment of risk factors for cancer. Our clinical focus is in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors.

If you are an FAP patient or know someone who is, you may be interested in a clinical trial that is recruiting participants in the United Kingdom, Germany, Spain, and the Netherlands, United States and Canada

Following Link Opens in New Window

Link to Trial Scroll down page for Contacts

Study Objective

This study will determine if a combination drug treatment works better than each drug alone in preventing FAP disease progression. It will also explore if the treatment can alter the course of the disease and determine how the combination impacts quality of life.


Patients may be eligible if they have FAP and

  • Have not had their colon removed, but are considering this surgery or,
  • Have advanced disease in the upper intestine or,
  • Have advanced disease in the pouch/rectum

If they meet one of those requirements, they may be eligible if:

  • They have a mutation in the APC gene. (If a patient has not been previously tested, their blood will be checked at the study site to determine if they are a carrier of the gene mutation.)
  • Are at least 18 years old

Treatment & Study Duration

The study explores two investigational oral medications: eflornithine and sulindac. All participants will receive at least 1 active drug. Participants will take 4 pills once a day for up to 2 years. It has been shown in several studies to reduce the growth of colon polyps but has not been approved by the FDA or EMA for this indication.

Additional Information

For additional trial information please go to:

Following Links Open in New Window or

Identifier: NCT01483144